Učitavanje...
Evaluation of Tyrosine Kinase Inhibitor Combinations for Glioblastoma Therapy
Glioblastoma multiforme (GBM) is the most common intracranial cancer but despite recent advances in therapy the overall survival remains about 20 months. Whole genome exon sequencing studies implicate mutations in the receptor tyrosine kinase pathways (RTK) for driving tumor growth in over 80% of GB...
Spremljeno u:
| Glavni autori: | , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Public Library of Science
2012
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3462750/ https://ncbi.nlm.nih.gov/pubmed/23056179 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0044372 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|